ArticleOncotarget2016
A targeted genetic association study of epithelial ovarian cancer susceptibility.
Abstract readComparative Study
In one paragraph
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of telomerase reverse transcriptase gene rs10069690 variant with cancer risk: an updated meta-analysis.BMC cancer · 2024Pooled it
- TERT rs10069690 polymorphism and cancers risk: A meta-analysis.Molecular genetics & genomic medicine · 2019Pooled it
- The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Review
- Association between 8q24 Gene Polymorphisms and the Risk of Prostate Cancer: A Systematic Review and Meta-Analysis.Journal of Cancer · 2017Article
- Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.Journal of Cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors.
Madalene EarpDepartment of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Stacey J WinhamDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Nicholas LarsonDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Jennifer B PermuthDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Hugues SicotteDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Jeremy ChienDepartment of Cancer Biology, University of Kansas Cancer Center, Kansas City, KS, USA.
Hoda Anton-CulverDepartment of Epidemiology, University of California Irvine, Irvine, CA, USA.
Elisa V BanderaRutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Andrew BerchuckDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Linda S CookDivision of Epidemiology and Biostatistics, University of New Mexico, Albuquerque, NM, USA.
Daniel CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Jennifer A DohertySection of Biostatistics and Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Marc T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Douglas A LevineGynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Alvaro N A MonteiroDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Roberta B NessThe University of Texas School of Public Health, Houston, TX, USA.
Celeste L PearceDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Mary Anne RossingDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
Shelley S TworogerDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Maria BisognaGynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Louise BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Angela Brooks-WilsonGenome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
Michael E CarneyClinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA.
Robert P EdwardsDepartment of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Zachary C FogartyDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Edwin S IversenDepartment of Statistical Science, Duke University, Durham, NC, USA.
Peter KraftDepartments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA, USA.
Melissa C LarsonDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Nhu D LeCancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
Hui-Yi LinDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jolanta LissowskaDepartment of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland.
Francesmary ModugnoDepartment of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, US.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Elizabeth M PooleChanning Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
David N RiderDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Pamela J ThompsonSamuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
David van den BergDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Robert A VierkantDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Allison F VitonisObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Lynne R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Hannah P YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Argyrios ZiogasDepartment of Epidemiology, Center for Cancer Genetics Research and Prevention, School of Medicine, University of California Irvine, Irvine, CA, USA.
Catherine M PhelanDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Joellen M SchildkrautDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
Yian Ann ChenDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Thomas A SellersDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Brooke L FridleyKansas IDeA Network of Biomedical Research Excellence Bioinformatics Core, University of Kansas Cancer Center, Kansas City, KS, USA.
Ellen L GoodeDepartment of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MHormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5MTRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MUniversity of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MWITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6MUSC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1985 to 2009
$18.2MNovel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3MCIHR MOP-86727CIHR MSH-87734Intramural NIH HHSNCI NIH HHS K07 CA080668NCI NIH HHS K07-CA080668NCI NIH HHS K07 CA092044NCI NIH HHS K07 CA095666NCI NIH HHS K07-CA095666NCI NIH HHS K22 CA138563NCI NIH HHS K22-CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01-CN-55424NCI NIH HHS N01 PC067010NCI NIH HHS N01-PC-67001NCI NIH HHS N01-PC67010NCI NIH HHS P01 CA017054NCI NIH HHS P01 CA087969NCI NIH HHS P01-CA17054NCI NIH HHS P01-CA87696NCI NIH HHS P30 CA008748NCI NIH HHS P30-CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA072720NCI NIH HHS P30-CA072720NCI NIH HHS P30-CA14089NCI NIH HHS P30-CA15083-41NCI NIH HHS P50 CA105009NCI NIH HHS P50-CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50-CA136393NCI NIH HHS P50 CA159981NCI NIH HHS P50-CA159981NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01-CA058860NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA087696NCI NIH HHS R01-CA092044NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01-CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01-CA122443NCI NIH HHS R01 CA149429NCI NIH HHS R01-CA-149429NCI NIH HHS R01-CA49449NCI NIH HHS R01-CA54419NCI NIH HHS R01-CA58598NCI NIH HHS R01-CA61132NCI NIH HHS R01-CA76016NCI NIH HHS R01-CA83918NCI NIH HHS R01-CA87538NCI NIH HHS R01-CA95023NCI NIH HHS R03 CA113148NCI NIH HHS R03-CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R03-CA115195NCI NIH HHS R35 CA197449NCI NIH HHS U19 CA148112NCI NIH HHS U19-CA148112NCRR NIH HHS M01 RR000056NCRR NIH HHS M01-RR000056PHS HHS PSA-042205
Abstract
backgroundGenome-wide association studies have identified several common susceptibility alleles for epithelial ovarian cancer (EOC). To further understand EOC susceptibility, we examined previously ungenotyped candidate variants, including uncommon variants and those residing within known susceptibility loci.
resultsAt nine of eleven previously published EOC susceptibility regions (2q31, 3q25, 5p15, 8q21, 8q24, 10p12, 17q12, 17q21.31, and 19p13), novel variants were identified that were more strongly associated with risk than previously reported variants. Beyond known susceptibility regions, no variants were found to be associated with EOC risk at genome-wide statistical significance (p <5x10(-8)), nor were any significant after Bonferroni correction for 17,000 variants (p< 3x10-6).
methodsA customized genotyping array was used to assess over 17,000 variants in coding, non-coding, regulatory, and known susceptibility regions in 4,973 EOC cases and 5,640 controls from 13 independent studies. Susceptibility for EOC overall and for select histotypes was evaluated using logistic regression adjusted for age, study site, and population substructure.
conclusionGiven the novel variants identified within the 2q31, 3q25, 5p15, 8q21, 8q24, 10p12, 17q12, 17q21.31, and 19p13 regions, larger follow-up genotyping studies, using imputation where necessary, are needed for fine-mapping and confirmation of low frequency variants that fall below statistical significance.
Indexed as
Genetic Association StudiesGenetic Predisposition to DiseaseBiomarkers, TumorCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleGene Expression ProfilingGenome-Wide Association StudyGenotypeHumansNeoplasms, Glandular and EpithelialNeoplasm StagingOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPolymorphism, Single NucleotidePrognosisBiomarkers, Tumorgenetic associationhigh-grade serous carcinomaNF-κBovarian cancersusceptibility loci
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.